Natera Expands Board, Appoints Eric Rubin as Director
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Natera ( (NTRA) ) has provided an update.
Natera’s Board of Directors has expanded from ten to eleven members and appointed Eric Rubin as an independent Class I director, effective March 26, 2026, with a term running until the 2028 annual meeting of stockholders. The board also named Dr. Rubin to its Nominating, Corporate Governance and Compliance Committee, indicating a continued emphasis on independent oversight and governance.
Dr. Rubin will receive cash and equity compensation aligned with other non-employee directors, with his initial equity grant vesting in three annual tranches from March 26, 2027, through March 26, 2029. Natera has also entered into a standard indemnification agreement with him and disclosed that he has no family relationships or material related-party transactions with current directors or executives, underscoring a focus on regulatory compliance and governance best practices.
The most recent analyst rating on (NTRA) stock is a Hold with a $185.00 price target. To see the full list of analyst forecasts on Natera stock, see the NTRA Stock Forecast page.
Spark’s Take on NTRA Stock
According to Spark, TipRanks’ AI Analyst, NTRA is a Neutral.
The score reflects improving fundamentals (strong growth, rising margins, stronger balance sheet, and positive cash generation) and a positive forward outlook from management guidance. These are offset by weak technical momentum (downtrend signals) and limited support from traditional valuation metrics due to ongoing losses and no dividend.
To see Spark’s full report on NTRA stock, click here.
More about Natera
Natera, Inc. is a Delaware-based medical diagnostics company specializing in genetic testing and analysis, including cell-free DNA technologies, for applications in oncology, women’s health, and organ health. The company focuses on leveraging advanced genomics and bioinformatics to provide precision medicine solutions to healthcare providers and patients in key global markets.
Average Trading Volume: 1,193,823
Technical Sentiment Signal: Buy
Current Market Cap: $28.34B
For detailed information about NTRA stock, go to TipRanks’ Stock Analysis page.
